Core Viewpoint - Alumis Inc. is a biopharmaceutical company focused on developing therapies for immune-mediated diseases, currently in late-stage clinical trials for moderate-to-severe plaque psoriasis with its drug envudeucitinib [1] Group 1: Stock Performance - The stock for ALMS is currently priced at $15.90, reflecting a significant increase of 91.33% with a change of $7.59 [3] - The stock has fluctuated between a low of $15.47 and a high of $22.30, marking its highest price over the past year, with the lowest price being $2.76 [3][6] - Derek Archila from Wells Fargo set a new price target for ALMS at $39, indicating a potential upside of 70.16% from its trading price of approximately $16.97 at the time [2][6] Group 2: Market Position - Alumis has a market capitalization of approximately $1.66 billion, reflecting its position in the biopharmaceutical industry [4][6] - The trading volume for the day is 53.93 million shares on the NASDAQ exchange, indicating heightened activity and interest in the stock [4][6] Group 3: Clinical Program - The announcement of the Phase 3 ONWARD clinical program results is a significant milestone for Alumis, with a conference call and webcast scheduled to discuss the results [5]
Alumis Inc. (NASDAQ: ALMS) Targets Immune-Mediated Diseases with Promising Clinical Trials